Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• Päätekijät: Ju Li (Tekijä), Zhongyuan Zhang (Tekijä), Xinhua Wu (Tekijä), Jie Zhou (Tekijä), Deqian Meng (Tekijä), Ping Zhu (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...